Comparative Pharmacology
Head-to-head clinical analysis: ERYC 125 versus PEDIAMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYC 125 versus PEDIAMYCIN.
ERYC 125 vs PEDIAMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin binds to the 50S subunit of bacterial ribosomes, inhibiting protein synthesis by blocking translocation of peptidyl-tRNA. It also activates motilin receptors in the gastrointestinal tract, enhancing gastric motility.
Erythromycin is a macrolide antibiotic that binds to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking translocation of peptidyl-tRNA. It may be bacteriostatic or bactericidal depending on concentration and organism.
250 mg orally every 6 hours or 500 mg every 12 hours; maximum 4 g/day.
250-500 mg orally every 6 hours; maximum 2 g/day.
None Documented
None Documented
1.5-2.0 hours in adults; prolonged in hepatic impairment (up to 5-6 hours) or neonates.
The terminal elimination half-life is approximately 1.5-2 hours in adults with normal renal function. In patients with severe hepatic impairment, half-life may be prolonged to 5-6 hours. The short half-life necessitates frequent dosing (every 6-8 hours) to maintain therapeutic levels.
Primarily hepatic metabolism; ~2-5% excreted unchanged in urine, ~15-20% in bile/feces as active drug.
PEDIAMYCIN (erythromycin ethylsuccinate) is primarily excreted via the biliary route (60-70% as unchanged drug and metabolites) with significant fecal elimination. Renal excretion accounts for only 5-15% of the dose, mostly as inactive metabolites. Less than 5% is excreted unchanged in urine.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic